1Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 [J]. Blood, 2008, 111(9) : 4477-4489.
2Stanulla N, Schrappe M. Treatment of childhood acute lymphoblastic leukemia [ J ]. Semin Hematol, 2009, 46 ( 1 ) : 52-63.
3Wester K, Jonsson A, Spigset O, et al. Spontaneously reported fatal suspected adverse drug reactions: a lO-year survey from Sweden [ J ]. Pharmacoepidemiology and drug safety, 2007, 16: 173-180.
4Esteve MA, Devictor Pierre B, Galy G, et al. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation [ J ]. Eur J Clin Pharmacol, 2007, 63 ( 1 ) : 3942.
5Kikuchi A, Mori T, Fujimoto J, et al. Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol [ J ]. Leuk Lymphoma, 2008, 49(4) : 757-762.
6Peter D, Maria J, Angela K et al. Pharmacodynamic properties of methotrexate and aminotrexate during weekly therapy [ J ]. Cancer Chemother pharmacol, 2006, 57: 826-834.
7Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo: a rationale for high dose methotrexat [J]. J Clin Invest, 1996, 97: 73-80.
8Galpin A J, Schuetz JD, Massin E, et al. Differences in folylpolyglutamatate sythetase and dihydrofolate reductase expression in human B-Lineage versus T-lineage leukemia lymphoblastic : mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity [ J ]. Mol Pharmacol, 1997, 52: 155-163.
6Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86 [J]. Blood, 1994,84:3122-3127.
7Peter D, Maria J, Angela K, et al. Pharmacodynamic properties of methotrexate and aminotrexate during weekly therapy[J]. Cancer Chemother Pharmacol, 2005, 57: 826-834.
8Evans WE, Crom WR, Abromowitch M, et al. Clinical phamacodynamic of high-dose methotrexate in acute lymphoblastic leukemia[J]. N Engl J Med, 1986,314:471-474.
9Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo : a rationale for high dose methotrexat[J]. J Clin Invest, 1996,97 : 73-80.
10Galpin AJ, Schuetz JD, Massin E, et al. Differences in folypolyglutamatate sythetase and dihydrofolate reductase expression in human B-Lineage versus T-lineage leukemia lymphoblastic: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity[J]. Mol Pharmacol, 1997, 52,155-163.
5Fotoohi K,Skarby T,Soderhall S,et al.Interference of 7-hydroxy-methotrexate with the determination of methotrexate in plasma sam-ples from children with acute lymphoblastic leukemia employingroutine clinical assays[J].J Chromatogr B Analyt Technol BiomedLife Sci,2005,817(2):139-144.
6Alnaim L.Therapeutic drug monitoring of cancer chemotherapy[J].J Oncol Pharm Pract,2007,13(4):207-221.
7Treon SP,Chabner BA. Concepts in use of high - dose methotrex-ate therapy[ J]. Clin Chem,1996,42(8) : 1322.
8Woessmann W, Seideraann K, Mann G, et al. The impact of themethotrexate administration schedule and dose in the treatment ofchildren and adolescents with B - cell neoplasms : a report of theBFM Group Study NHL-BFM95[ J]. Blood,2005 ,105(3) :948.
9Millot F,Rubie H,Mazingue F,et al. Cerebrospinal fluid drug lev-els of leukemic children receiving intravenous 5 g/m2 methotrexate[J]. Leuk Lymphoma,1994,14( 1/2) : 141.
10Rask C,Albertioni F,Bentzen S M,et al. Clinical and pharmacoki-netic risk factors for high - dose methotrexate - induced toxicity inchildren with acute lymphoblastic leukemia - a logistic regressionanalysis [J]. Acta Oncol,199Bt37(3) :277 -284.
